Disease · MONDO_0056806

non-small cell squamous lung carcinoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. non-small cell squamous lung carcinoma. Diseases, record MONDO_0056806. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0056806

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: non-small cell squamous lung carcinoma; Open Targets
Open Targets ID: MONDO_0056806; Open Targets
Other names: non-small cell squamous lung cancer, squamous non-small cell lung carcinoma; Open Targets
Disease Ontology: DOID:0080521; Disease Ontology
NCI Thesaurus: C133254; NCI Thesaurus
Highest stage of its drugs: Approval, for 2 of its 80 drugs, from PMDA; Open Targets

Drugs80

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
BEVACIZUMAB	CHEMBL1201583	Antibody	Approval	PMDA	22	21	21	Drugs and targets
NECITUMUMAB	CHEMBL1743047	Antibody	Approval	PMDA	2	1	1	Drugs and targets
CARBOPLATIN	CHEMBL1351	Small molecule	Phase 3	ClinicalTrials.gov	34	34	34	Drugs and targets
PEMETREXED	CHEMBL225072	Small molecule	Phase 3	ClinicalTrials.gov	24	24	24	Drugs and targets
PACLITAXEL	CHEMBL428647	Small molecule	Phase 3	ClinicalTrials.gov	23	23	23	Drugs and targets
CISPLATIN	CHEMBL11359	Small molecule	Phase 3	ClinicalTrials.gov	16	16	16	Drugs and targets
PEMBROLIZUMAB	CHEMBL3137343	Antibody	Phase 3	ClinicalTrials.gov	11	11	11	Drugs and targets
GEMCITABINE	CHEMBL888	Small molecule	Phase 3	ClinicalTrials.gov	7	7	7	Drugs and targets
RIVOCERANIB	CHEMBL3186534	Small molecule	Phase 3	ClinicalTrials.gov	6	6	6	Drugs and targets
SINTILIMAB	CHEMBL4297829	Antibody	Phase 3	ClinicalTrials.gov	6	6	6	Drugs and targets

1 to 10 of 80

See all 80 drugs

Targets85

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
PDCD1	Programmed cell death protein 1	9	Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor	Phase 3	https://conductscience.org/library/genes/5133	Drugs and targets
EGFR	Epidermal growth factor receptor	6	Epidermal growth factor receptor erbB1 inhibitor	Approval	https://conductscience.org/library/genes/1956	Drugs and targets
TUBA1A	Tubulin	6	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	6	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/10376	Drugs and targets
TUBA1C	Tubulin	6	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/84790	Drugs and targets
TUBA3C	Tubulin	6	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7278	Drugs and targets
TUBA3E	Tubulin	6	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/112714	Drugs and targets
TUBA4A	Tubulin	6	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7277	Drugs and targets
TUBB	Tubulin	6	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/203068	Drugs and targets
TUBB1	Tubulin	6	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/81027	Drugs and targets

1 to 10 of 85

See all 85 targets

Trials100

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02364999	A Comparative Study Of PF-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel-Carboplatin Patients With Advanced Non-Squamous NSCLC	Phase 3	719	2018-06-27	Non-Small Cell Lung Cancer	BEVACIZUMAB, CARBOPLATIN, PACLITAXEL	Open Targets' reading of its record	ClinicalTrials.gov
NCT03631199	Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects	Phase 3	673	2024-10-08	Non-small Cell Lung Cancer	CANAKINUMAB, CARBOPLATIN, CISPLATIN, PACLITAXEL, PEMBROLIZUMAB, PEMETREXED	Open Targets' reading of its record	ClinicalTrials.gov
NCT03296163	A Study Comparing MB02 and Avastin® in Subjects With Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)	Phase 3	627	2021-03-26	Non-small Cell Lung Cancer	BEVACIZUMAB, CARBOPLATIN, PACLITAXEL	Open Targets' reading of its record	ClinicalTrials.gov
NCT02409342	A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]	Phase 3	572	2021-02-18	Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer	ATEZOLIZUMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT01454102	Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)	Phase 1	472	2019-08-05	Non-small Cell Lung Cancer	BEVACIZUMAB, CARBOPLATIN, CISPLATIN, ERLOTINIB, GEMCITABINE, IPILIMUMAB, NIVOLUMAB, PACLITAXEL, PEMETREXED	Open Targets' reading of its record	ClinicalTrials.gov
NCT02027428	Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung Cancer	Phase 3	427	2018-12-07	Squamous Cell Carcinoma, Non-Small-Cell Lung	CARBOPLATIN, PACLITAXEL	Open Targets' reading of its record	ClinicalTrials.gov
NCT03594747	A Study of Tislelizumab in Combination With Chemotherapy Versus Chemotherapy in Advanced Lung Cancer	Phase 3	360	2023-10-17	Non-Small Cell Lung Cancer	CARBOPLATIN, PACLITAXEL, TISLELIZUMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT03150875	A Study Comparing the Efficacy and Safety Between IBI308 and Docetaxel in Patients With Advanced or Metastatic NSCLC	Phase 3	290	2021-06-23	Non-small Cell Lung Cancer	DOCETAXEL, SINTILIMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT02937116	First in Human Study of IBI308 in Chinese Subjects With Advanced Solid Tumors	Phase 1	233	2021-02-21	Cancer, Solid Tumor	CAPECITABINE, CISPLATIN, ETOPOSIDE, FLUOROURACIL, GEMCITABINE, IRINOTECAN, OXALIPLATIN, PEMETREXED, SINTILIMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT04579380	Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations	Phase 2	217	2024-11-13	Uterine Neoplasms, Uterine Cervical Neoplasms, Biliary Tract Neoplasms, Urologic Neoplasms, Carcinoma, Non-Small-Cell Lung, HER2 Mutations Breast Neoplasms	FULVESTRANT, TRASTUZUMAB, TUCATINIB	Open Targets' reading of its record	ClinicalTrials.gov

1 to 10 of 100

See all 100 trials

Comparisons in its trials19

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
PF-06439535 vs Bevacizumab-EU: Number of Participants With Laboratory Abnormalities (Without Regard to Baseline Abnormality)	303 of 342	304 of 348	690	NCT02364999	Trial comparisons
MB02 (Bevacizumab Biosimilar Drug) vs EU-approved Avastin®: deaths from any cause	23 of 311	24 of 310	621	NCT03296163	Trial comparisons
MB02 (Bevacizumab Biosimilar Drug) vs EU-approved Avastin®: serious adverse events	58 of 311	54 of 310	621	NCT03296163	Trial comparisons
Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) vs Atezolizumab: deaths from any cause	211 of 287	201 of 285	572	NCT02409342	Trial comparisons
Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) vs Atezolizumab: serious adverse events	77 of 263	97 of 286	549	NCT02409342	Trial comparisons
Sintilimab vs Docetaxel: deaths from any cause	108 of 144	101 of 130	274	NCT03150875	Trial comparisons
Sintilimab vs Docetaxel: serious adverse events	56 of 144	34 of 130	274	NCT03150875	Trial comparisons
Crizotinib vs Chemotherapy: deaths from any cause	62 of 104	61 of 101	205	NCT01639001	Trial comparisons
Crizotinib vs Chemotherapy: serious adverse events	46 of 104	13 of 101	205	NCT01639001	Trial comparisons
Lenvatinib vs Lenvatinib Matched Placebo: serious adverse events	46 of 89	21 of 46	135	NCT01529112	Trial comparisons

1 to 10 of 19

See all 19 comparisons in its trials

Papers from its trials92

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
41125109	RESULT	1	PubMed
40528044	RESULT	1	PubMed
40057343	RESULT	1	PubMed
38642937	RESULT	1	PubMed
37879536	RESULT	1	PubMed
35875118	RESULT	1	PubMed
34358724	RESULT	1	PubMed
34327136	RESULT	1	PubMed
33791214	RESULT	1	PubMed
33433946	RESULT	1	PubMed

1 to 10 of 92

See all 92 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0056806

GET https://conductscience.org/api/diseases/v1/MONDO_0056806/drugs?page=2

API reference For AI assistants